STALICLA becomes a clinical stage company, with the approval of its STP1 investigational new drug (IND) application by the FDA

STP1 is the first precision treatment to enter the clinic for a biologically-defined subgroup of patients with autism spectrum disorder.

Read more

Swiss Biotech STALICLA Announces Closure of USD 8M (CHF 7.7) for Second Tranche of Series A

STALICLA SA, a near clinical stage Swiss Biotech company leading the field of precision medicine for Neurodevelopmental Disorders (NDDs) - including conditions like Autism Spectrum Disorder (ASD) or Developmental Delay - today announced the successful closure of the second tranche of its series A for an amount of USD 8M (CHF 7.7M).

Read more

Bilan – Janvier 2020 : Innovation - featuring STALICLA CEO

Lynn Durham, fondatrice de la startup genevoise Stalicla, veut proposer un traitement personnalisé adapté à chaque patient.

Read more

STALICLA CEO & Founder, Lynn-Allison Durham will be speaking January 12th, 2020 on NeuroTech, software and diagnostics expert panel at SACHS Neuroscience Innovation Forum_Pre-JP Morgan, in San Francisco.

CEO & Founder,  will be speaking on expert panel on NeuroTech, software and diagnostics- at hashtagSACHS_NIF _Pre-JP Morgan in San Francisco. She will share STALICLA’s experience of developing a highly domain specific AI platform to accelerate precision medicine for patients with neurodevelopmental disorders

Read more

Search for content on Stalicla...